Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
NCT02697552
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
13
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG:
HBI-8000
Sponsor
HUYABIO International, LLC.